HTG Molecular Diagnostics Expands Collaboration with Merck KGaA

Dec 28, 2017
By BioPharm International Editors

On Dec. 26, 2017, HTG Molecular Diagnostics, a provider of instruments, reagents, and services for molecular profiling applications, announced that it has entered into a new master collaboration agreement with Merck KGaA, Darmstadt, Germany.

According to HTG, this master collaboration agreement complements a previously announced master companion diagnostic agreement with Merck KGaA and includes a statement of work with EMD Serono, the biopharmaceutical business of Merck KGaA in the United States and Canada.

Under the terms of the agreement, HTG plans to develop and manufacture a custom profiling assay to support biomarker research for six indications within Merck KGaA’s drug development pipeline.  The assay is expected to be kitted for use on HTG EdgeSeq instruments acquired by Merck KGaA and/or their contract research organization partners.

“We are pleased to expand our relationship with Merck KGaA, Darmstadt, Germany, into earlier research stages of their programs, and have already begun work on an initial custom assay development program,” said TJ Johnson, president and CEO at HTG, in a company press release.

Source: HTG Molecular Diagnostics

lorem ipsum